306 related articles for article (PubMed ID: 14606985)
21. Association between second-generation antipsychotic medication half-life and hospitalization in the community treatment of adult schizophrenia.
Broder MS; Bates JA; Jing Y; Hebden T; Forbes RA; Chang E
J Med Econ; 2012; 15(1):105-11. PubMed ID: 21991926
[TBL] [Abstract][Full Text] [Related]
22. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Olfson M; Blanco C; Liu L; Moreno C; Laje G
Arch Gen Psychiatry; 2006 Jun; 63(6):679-85. PubMed ID: 16754841
[TBL] [Abstract][Full Text] [Related]
23. Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia.
Lang K; Federico V; Muser E; Menzin J; Menzin J
J Med Econ; 2013 Aug; 16(8):997-1006. PubMed ID: 23777223
[TBL] [Abstract][Full Text] [Related]
24. National trends in psychotropic medication polypharmacy in office-based psychiatry.
Mojtabai R; Olfson M
Arch Gen Psychiatry; 2010 Jan; 67(1):26-36. PubMed ID: 20048220
[TBL] [Abstract][Full Text] [Related]
25. Validity of the adherence estimator in the prediction of 9-month persistence with medications prescribed for chronic diseases: a prospective analysis of data from pharmacy claims.
McHorney CA; Victor Spain C; Alexander CM; Simmons J
Clin Ther; 2009 Nov; 31(11):2584-607. PubMed ID: 20110004
[TBL] [Abstract][Full Text] [Related]
26. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis.
Nasr SZ; Chou W; Villa KF; Chang E; Broder MS
J Med Econ; 2013; 16(6):801-8. PubMed ID: 23506540
[TBL] [Abstract][Full Text] [Related]
27. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
28. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost.
Silberstein SD; Feliu AL; Rupnow MF; Blount AC; Boccuzzi SJ
Headache; 2007 Apr; 47(4):500-10. PubMed ID: 17445099
[TBL] [Abstract][Full Text] [Related]
29. Patterns of atypical antipsychotic therapy use in adults with bipolar I disorder in the USA.
Chen W; Deveaugh-Geiss AM; Palmer L; Princic N; Chen YT
Hum Psychopharmacol; 2013 Sep; 28(5):428-37. PubMed ID: 23861367
[TBL] [Abstract][Full Text] [Related]
30. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
31. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication.
Martin BC; Wiley-Exley EK; Richards S; Domino ME; Carey TS; Sleath BL
Ann Pharmacother; 2009 Jan; 43(1):36-44. PubMed ID: 19126828
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of health care costs and utilization patterns for patients with gout.
Park H; Rascati KL; Prasla K; McBayne T
Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
[TBL] [Abstract][Full Text] [Related]
33. Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.
Farley JF; Cline RR; Schommer JC; Hadsall RS; Nyman JA
Clin Ther; 2008 Aug; 30(8):1524-39; discussion 1506-7. PubMed ID: 18803994
[TBL] [Abstract][Full Text] [Related]
34. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data.
Karve S; Cleves MA; Helm M; Hudson TJ; West DS; Martin BC
Curr Med Res Opin; 2009 Sep; 25(9):2303-10. PubMed ID: 19635045
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population.
Hodgkins P; Sasané R; Christensen L; Harley C; Liu F
Curr Med Res Opin; 2011; 27 Suppl 2():53-62. PubMed ID: 21973231
[TBL] [Abstract][Full Text] [Related]
37. Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral.
Offord S; Wong B; Mirski D; Baker RA; Lin J
J Med Econ; 2013; 16(2):231-9. PubMed ID: 23163287
[TBL] [Abstract][Full Text] [Related]
38. The association between class of antipsychotic and rates of hospitalization: results of a retrospective analysis of data from the 2005 Medicare current beneficiary survey.
Kennedy J; Tien YY; Cohen LJ; Sclar DA; Liu D; Blodgett EG; Engle J
Clin Ther; 2009 Dec; 31(12):2931-9. PubMed ID: 20110033
[TBL] [Abstract][Full Text] [Related]
39. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.
Ivanova JI; Bergman RE; Birnbaum HG; Phillips AL; Stewart M; Meletiche DM
J Med Econ; 2012; 15(3):601-9. PubMed ID: 22376190
[TBL] [Abstract][Full Text] [Related]
40. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
